Abstract

A CRITICAL REVIEW OF ANALYTICAL AND BIO-ANALYTICAL METHODS FOR THE ESTIMATION OF ANTI-HIV DRUG BICTEGRAVIR

Rudranil Karmakar, Dr. J.S.K. Nagarajan*, Debarya Banerjee, Shambhavi Shahi,

.

Abstract

Bictegravir is an antiviral drug of the „Integrase Strand Transfer Inhibitor‟ class that was structurally derived from an earlier compound Dolutegravir. The drug has demonstrated favorable outcomes in managing HIV-1 and HIV-2 infections and has received authorization for HIV-1 monotherapy in conjunction with two other antiretroviral medications in a single tablet.[1] Bictegravir is a recommended treatment for patients who have not undergone antiretroviral therapy and are diagnosed with HIV-1 infection. This is an enzyme encoded by the HIV-1 virus that is essential for the virus to replicate. The prevention of the integration of HIV-1 into the host DNA is achieved through the inhibition of the integrase enzyme. This action effectively blocks the conversion of the HIV-1 provirus and impedes the progression of the virus.[2] [3] Although this drug is used extensively, only limited studies have been conducted. This article is intended to highlight the analytical and bio-analytical methods such as UV, HPLC, LC-MS/MS, UHPLC-MS has been used for the estimation of Bictegravir as individual as well as in pharmaceutical dosage form in combination with other drugs. Many analytical and bio-analytical methods have been reported for the estimation of Bictegravir individually as well as in combination.

Keywords: HIV Infection, UV-Spectrophotometry, EMT, TAF, RP-HPLC, LC-MS/MS, UHPLC-MS/MS, Mobile Phase, Column, Wavelength, Flow rate, m/z ratio, EMT, TAF.